V

    VistaGen Therapeutics Inc (VTGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.26
    +0.00 (+0.83%)

    Market Cap: $11.32M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -20.50%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.37
    Range$-0.37 - $-0.37
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.28+24.3%
    60d ago$-0.24+34.2%
    30d ago$-0.38-1.4%
    7d ago$-0.38-1.4%
    Current$-0.37
    Revenue Consensus
    $166670
    Range$0 - $500000
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.36
    Range$-0.36 - $-0.36
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.28+20.8%
    60d ago$-0.24+33.3%
    30d ago$-0.36-1.4%
    7d ago$-0.36-1.4%
    Current$-0.36
    Revenue Consensus
    $166670
    Range$0 - $500000
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.35---
    Dec 26EST
    		-$-0.36---
    Sep 26EST
    		-$-0.37---
    Jun 26
    Reported Aug 14
    		$-0.30$-0.29-3.45%Miss+36.2%
    Mar 26
    Reported Jun 15
    		$-0.37$-0.42+11.90%Beat+15.9%
    Dec 25
    Reported Feb 12
    		$-0.45$-0.48+6.25%Beat+2.2%
    Sep 25
    Reported Nov 13
    		$-0.54$-0.44-22.73%Miss-28.6%
    Jun 25
    Reported Aug 7
    		$-0.47$-0.47+0.00%Beat-34.3%
    Mar 25
    Reported Jun 17
    		$-0.44$-0.85+48.24%Beat-76.0%
    Dec 24
    Reported Feb 13
    		$-0.46$-0.52+11.54%Beat-109.1%
    Sep 24
    Reported Nov 7
    		$-0.42$-0.39-7.69%Miss+36.4%
    Jun 24
    Reported Aug 13
    		$-0.35$-0.40+12.50%Beat+62.8%
    Mar 24
    Reported Jun 11
    		$-0.25$-0.36+30.56%Beat+85.7%
    Dec 23
    Reported Feb 13
    		$-0.22$-0.27+18.52%Beat+85.3%
    Sep 23
    Reported Nov 9
    		$-0.66$-0.68+2.94%Beat+72.5%
    Jun 23
    Reported Aug 10
    		$-0.94$-0.86-9.30%Miss+68.7%
    Mar 23
    Reported Jun 22
    		$-1.75$-1.50-16.67%Miss-1844.4%
    Dec 22
    Reported Feb 7
    		$-1.50$-1.80+16.67%Beat+0.0%
    Sep 22
    Reported Nov 10
    		$-2.40$-0.60-300.00%Miss-14.3%
    Jun 22
    Reported Aug 11
    		$-3.00$-2.25-33.33%Miss-150.0%
    Mar 22
    Reported Jun 23
    		$-0.09$-0.06-50.00%Miss+55.0%
    Dec 21
    Reported Feb 10
    		$-1.50$-2.25+33.33%Beat+28.6%
    Sep 21
    Reported Nov 10
    		$-2.10$-2.25+6.67%Beat-40.0%
    Jun 21
    Reported Aug 12
    		$-1.20$-1.80+33.33%Beat+42.9%
    Mar 21
    Reported Jun 29
    		$-0.20$-0.05-300.00%Miss-185.7%
    Dec 20
    Reported Feb 11
    		$-2.10$-1.60-31.25%Miss+53.3%
    Sep 20
    Reported Nov 12
    		$-1.50$-0.70-114.29%Miss+61.5%
    Jun 20
    Reported Aug 13
    		$-2.10$-3.00+30.00%Beat+53.3%
    Mar 20
    Reported Jun 29
    		$-0.07$-0.08+12.50%Beat+58.8%
    Dec 19
    Reported Feb 13
    		$-4.50$-2.10-114.29%Miss+37.5%
    Sep 19
    Reported Nov 7
    		$-3.90$-4.05+3.70%Beat+56.7%
    Jun 19
    Reported Aug 16
    		$-4.50$-3.30-36.36%Miss+25.0%
    Mar 19
    Reported Jun 25
    		$-0.17$-0.12-41.67%Miss-88.9%
    Dec 18
    Reported Feb 12
    		$-7.20$-6.45-11.63%Miss+4.0%
    Sep 18
    Reported Oct 29
    		$-9.00$-5.10-76.47%Miss-1598.1%
    Jun 18
    Reported Aug 14
    		$-6.00$-4.20-42.86%Miss+28.6%
    Mar 18
    Reported Jun 26
    		$-0.09N/A+78.05%Beat+71.0%
    Dec 17
    Reported Feb 12
    		$-7.50$-8.10+7.41%Beat+26.5%
    Sep 17
    Reported Nov 9
    		$-0.53$-0.38-39.47%Miss+95.8%
    Jun 17
    Reported Aug 14
    		$-8.40$-12.30+31.71%Beat-
    Mar 17
    Reported Jun 29
    		$-0.31$-0.50+38.00%Beat-
    Dec 16
    Reported Feb 13
    		$-10.20$-11.10+8.11%Beat-
    Sep 16
    Reported Nov 14
    		$-12.60$-11.40-10.53%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.15EV/EBITDA-0.19x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-904.00%
    ROE-166.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.07xQuick Ratio3.07x
    Trading Statistics
    Beta0.38Avg Volume6.88M
    52-Week High$5.1452-Week Low$0.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.25
    SMA 20$0.26
    SMA 50$0.30
    SMA 200$0.98
    EMA 10$0.25
    EMA 20$0.26
    EMA 50$0.32
    EMA 200$0.95

    MACD

    Line: -0.01Signal: -0.02Hist: 0.00

    ADX

    ADX: 13.4+DI: 18.7-DI: 20.8

    Aroon & PSAR

    Aroon Up24.0
    Aroon DownN/A
    PSAR$0.45

    Bollinger Bands

    Upper Band$0.30
    Lower Band$0.23
    %B Position2725%(Upper)
    Band Width0.40

    RSI (14-Day)

    Neutral
    44.3

    Momentum Oscillators

    Stoch %K44.9
    Stoch %D38.0
    Williams %R-46.9
    ROC (10d)-1.9%
    Momentum-0.01
    CCI (20d)-48.4
    MFI (14d)41.5

    Volatility Measures

    ATR (14d)$0.02(8.8%)
    StdDev (20d)0.02
    Hist Vol96.3%(High)

    Volume Flow

    VWAP$0.25
    OBV6.5M
    AD Line53.5M
    CMF (20d)0.260

    Volume Metrics

    Avg Vol (20d)7.2M
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.29

    Pivot Points

    R3$0.27
    R2$0.27
    R1$0.26
    Pivot Point$0.25
    S1$0.25
    S2$0.24
    S3$0.23

    Advanced Oscillators

    TSI-15.92
    Ultimate Osc52.4
    KST-1.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.48M$464,000$303,000$258,000$244,000$-15,000$234,000$183,000$84,000$198,000$411,000$278,000
    Cost of Revenue$0$389,000$0$0$0$161,000$0$0$0$146,500$0$0
    Gross Profit$1.48M$464,000$303,000$258,000$244,000$-15,000$234,000$183,000$84,000$198,000$411,000$278,000
    Operating Expenses$14.82M$17.19M$19.85M$20.31M$16.05M$14.48M$15.35M$14.41M$12.21M$11.56M$8.29M$7.06M
    R&D$10.91M$13.16M$14.22M$15.91M$11.68M$10.21M$11.30M$10.21M$7.65M$7.44M$4.54M$3.85M
    SG&A$3.92M$4.03M$5.63M$4.40M$4.37M$4.27M$4.05M$4.20M$4.57M$4.12M$3.76M$3.21M
    Operating Income$-13,348,000$-16,723,000$-19,546,000$-20,053,000$-15,804,000$-14,495,000$-15,120,000$-14,227,000$-12,131,000$-11,359,000$-7,884,000$-6,780,000
    Interest Income$319,000$453,000$647,000$630,000$711,000$855,000$1.03M$1.27M$1.40M$1.53M$1.53M$192,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-13,030,000$-16,267,000$-18,899,000$-19,417,000$-15,095,000$-13,635,000$-14,089,000$-12,954,000$-10,733,000$-9,520,000$-6,350,000$-6,588,000
    Income Tax Expense$0$7,000$0$0$0$0$0$7,000$0$1,000$0$0
    Net Income$-13,030,000$-16,274,000$-18,899,000$-19,417,000$-15,095,000$-13,635,000$-14,089,000$-12,961,000$-10,733,000$-9,521,000$-6,350,000$-6,588,000
    EBITDA$-13,152,000$-16,530,000$-19,357,000$-19,862,000$-15,637,000$-14,324,000$-14,959,000$-14,070,000$-11,980,000$-11,212,000$-7,741,000$-6,641,000
    EBIT$-13,349,000$-16,720,000$-19,546,000$-20,047,000$-15,806,000$-14,490,000$-15,120,000$-14,227,000$-12,131,000$-11,359,000$-7,884,000$-6,780,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VTGN

    News

    Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN

    Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial for fasedienol and fund general corporate purposes.

    Moomoo•8/15/26•
    Somewhat-Bullish

    Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure

    Vistagen Therapeutics reported a net loss of $13.0 million for Q1 2027, an improvement from the prior year, with revenue increasing to $1.5 million. Despite this, the company flagged substantial doubt about its ability to continue as a going concern due to high operating expenses and a dwindling cash reserve of $31.7 million, with $14.7 million used in operating activities during the quarter. Vistagen also faces pressure from Nasdaq to regain compliance with the $1.00 minimum bid price requirement by February 1, 2027.

    Stock Titan•8/15/26•
    Bearish

    William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating

    William Blair has reiterated its Hold rating for VistaGen Therapeutics (VTGN.US). The report from the investment firm indicates their continued neutral stance on the company's stock.

    Moomoo•8/15/26•
    Neutral

    Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake

    Commodore Capital LP and related entities have reported a 9.9% beneficial ownership stake in Vistagen Therapeutics (VTGN), totaling 4,244,590 shares as of June 30, 2026. This stake includes common shares and shares underlying Tranche 1 and Tranche 2 Warrants, with the warrants subject to a 9.99% beneficial ownership limitation. The filing indicates shared voting and dispositive power among the reporting persons.

    Stock Titan•8/14/26•
    Neutral

    Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake

    Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general partners, accumulating to 2,960,404 warrant shares. This ownership is subject to a 9.99% Beneficial Ownership Limitation that restricts warrant exercises above that level.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About VTGN

    Does VTGN pay dividends?
    VistaGen Therapeutics Inc (VTGN) does not currently pay a regular dividend.
    What is VTGN's market cap?
    VistaGen Therapeutics Inc (VTGN) has a market capitalization of $11.32M with a current stock price of $0.26.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In